<code id='4812376B60'></code><style id='4812376B60'></style>
    • <acronym id='4812376B60'></acronym>
      <center id='4812376B60'><center id='4812376B60'><tfoot id='4812376B60'></tfoot></center><abbr id='4812376B60'><dir id='4812376B60'><tfoot id='4812376B60'></tfoot><noframes id='4812376B60'>

    • <optgroup id='4812376B60'><strike id='4812376B60'><sup id='4812376B60'></sup></strike><code id='4812376B60'></code></optgroup>
        1. <b id='4812376B60'><label id='4812376B60'><select id='4812376B60'><dt id='4812376B60'><span id='4812376B60'></span></dt></select></label></b><u id='4812376B60'></u>
          <i id='4812376B60'><strike id='4812376B60'><tt id='4812376B60'><pre id='4812376B60'></pre></tt></strike></i>

          Home / knowledge / knowledge

          knowledge


          knowledge

          author:fashion    Page View:833
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In